Raymond James Downgrades PacWest Banc to Market Perform
Raymond James analyst David Long downgrades PacWest Banc (NASDAQ:PACW) from Strong Buy to Market Perform.
Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics
Verve Therapeutics Inc (NASDAQ:VERV) entered into an Amended and Restated Collaboration and License Agreement with Beam Therapeutics Inc (NASDAQ:BEAM), which amended…
Raymond James Maintains Outperform on Azul, Lowers Price Target to $12
Raymond James analyst Savanthi Syth maintains Azul (NYSE:AZUL) with a Outperform and lowers the price target from $22 to $12.
Citigroup Maintains Buy on Spotify Technology, Lowers Price Target to $150
Citigroup analyst Jason Bazinet maintains Spotify Technology (NYSE:SPOT) with a Buy and lowers the price target from $165 to $150.
Raymond James Maintains Strong Buy on Huntington Bancshares, Lowers Price Target to $16
Raymond James analyst David Long maintains Huntington Bancshares (NASDAQ:HBAN) with a Strong Buy and lowers the price target from $18 to $16.
Raymond James Downgrades Horizon Bancorp to Outperform, Lowers Price Target to $22
Raymond James analyst David Long downgrades Horizon Bancorp (NASDAQ:HBNC) from Strong Buy to Outperform and lowers the price target from $23 to $22.
$1.4 Million Bet On This Healthcare Stock? 4 Penny Stocks Insiders are Buying
U.S. stock futures traded higher this morning on Thursday after closing slightly higher on Wednesday. Investors, meanwhile, focused on some notable insider trades.
Raymond James Downgrades Lakeland Bancorp to Outperform, Lowers Price Target to $17
Raymond James analyst William Wallace downgrades Lakeland Bancorp (NASDAQ:LBAI) from Strong Buy to Outperform and lowers the price target from $20 to $17.
Citigroup Maintains Neutral on Qurate Retail, Lowers Price Target to $3
Citigroup analyst Jason Bazinet maintains Qurate Retail (NASDAQ:QRTEA) with a Neutral and lowers the price target from $4 to $3.
Morgan Stanley Maintains Overweight on S&P Global, Lowers Price Target to $398
Morgan Stanley analyst Toni Kaplan maintains S&P Global (NYSE:SPGI) with a Overweight and lowers the price target from $401 to $398.